244 related articles for article (PubMed ID: 19505380)
1. Strategies for successful vaccination against hepatocellular carcinoma.
Rinaldi M; Iurescia S; Fioretti D; Ponzetto A; Carloni G
Int J Immunopathol Pharmacol; 2009; 22(2):269-77. PubMed ID: 19505380
[TBL] [Abstract][Full Text] [Related]
2. Immunobiology and gene-based immunotherapy of hepatocellular carcinoma.
Geissler M; Mohr L; Ali MY; Grimm CF; Ritter M; Blum HE
Z Gastroenterol; 2003 Nov; 41(11):1101-10. PubMed ID: 14648380
[TBL] [Abstract][Full Text] [Related]
3. Dendritic cell as therapeutic vaccines against tumors and its role in therapy for hepatocellular carcinoma.
Sun K; Wang L; Zhang Y
Cell Mol Immunol; 2006 Jun; 3(3):197-203. PubMed ID: 16893500
[TBL] [Abstract][Full Text] [Related]
4. Patient-derived dendritic cells transduced with an a-fetoprotein-encoding adenovirus and co-cultured with autologous cytokine-induced lymphocytes induce a specific and strong immune response against hepatocellular carcinoma cells.
González-Carmona MA; Märten A; Hoffmann P; Schneider C; Sievers E; Schmidt-Wolf IG; Sauerbruch T; Caselmann WH
Liver Int; 2006 Apr; 26(3):369-79. PubMed ID: 16584401
[TBL] [Abstract][Full Text] [Related]
5. Immunotherapeutic strategies for hepatocellular carcinoma.
Butterfield LH
Gastroenterology; 2004 Nov; 127(5 Suppl 1):S232-41. PubMed ID: 15508089
[TBL] [Abstract][Full Text] [Related]
6. The role of the immune system in the control of hepatocellular carcinoma.
O'Beirne JP; Harrison PM
Eur J Gastroenterol Hepatol; 2004 Nov; 16(12):1257-60. PubMed ID: 15618828
[TBL] [Abstract][Full Text] [Related]
7. Antigen-specific T cell response from dendritic cell vaccination using side population cell-associated antigens targets hepatocellular carcinoma.
Li X; Zhang Z; Lin G; Gao Y; Yan Z; Yin H; Sun B; Wang F; Zhang H; Chen H; Cao D
Tumour Biol; 2016 Aug; 37(8):11267-78. PubMed ID: 26951511
[TBL] [Abstract][Full Text] [Related]
8. Immunotherapy based on dendritic cells pulsed with CTPFoxM1 fusion protein protects against the development of hepatocellular carcinoma.
Su H; Li B; Zheng L; Wang H; Zhang L
Oncotarget; 2016 Jul; 7(30):48401-48411. PubMed ID: 27351282
[TBL] [Abstract][Full Text] [Related]
9. Cellular immune responses to hepatocellular carcinoma: lessons for immunotherapy.
Schmidt N; Neumann-Haefelin C; Thimme R
Dig Dis; 2012; 30(5):483-91. PubMed ID: 23108304
[TBL] [Abstract][Full Text] [Related]
10. Comparative analysis of DC fused with allogeneic hepatocellular carcinoma cell line HepG2 and autologous tumor cells as potential cancer vaccines against hepatocellular carcinoma.
Cao DY; Yang JY; Yue SQ; Tao KS; Song ZS; Wang DS; Yang YL; Dou KF
Cell Immunol; 2009; 259(1):13-20. PubMed ID: 19545862
[TBL] [Abstract][Full Text] [Related]
11. Immunotherapeutic strategies for treatment of hepatocellular carcinoma with antigen-loaded dendritic cells: in vivo study.
El-Ashmawy NE; El-Zamarany EA; Khedr EG; El-Bahrawy HA; El-Feky OA
Clin Exp Med; 2018 Nov; 18(4):535-546. PubMed ID: 30062618
[TBL] [Abstract][Full Text] [Related]
12. Effect of dendritic cell-based immunotherapy on hepatocellular carcinoma: A systematic review and meta-analysis.
Chen C; Ma YH; Zhang YT; Zhang F; Zhou N; Wang X; Liu T; Li YM
Cytotherapy; 2018 Aug; 20(8):975-989. PubMed ID: 30072299
[TBL] [Abstract][Full Text] [Related]
13. Alarmin augments the antitumor immunity of lentiviral vaccine in ectopic, orthotopic and autochthonous hepatocellular carcinoma mice.
Liu Z; Lu Z; Jing R; Zuo B; Gao X; Han G; Qi H; Wu L; Liu Y; Yin H
Theranostics; 2019; 9(14):4006-4018. PubMed ID: 31281528
[TBL] [Abstract][Full Text] [Related]
14. Improvement of dendritic-based vaccine efficacy against hepatitis B virus-related hepatocellular carcinoma by two tumor-associated antigen gene-infected dendritic cells.
Yang JY; Cao DY; Xue Y; Yu ZC; Liu WC
Hum Immunol; 2010 Mar; 71(3):255-62. PubMed ID: 20036295
[TBL] [Abstract][Full Text] [Related]
15. A phase I/IIa study of adjuvant immunotherapy with tumour antigen-pulsed dendritic cells in patients with hepatocellular carcinoma.
Lee JH; Lee Y; Lee M; Heo MK; Song JS; Kim KH; Lee H; Yi NJ; Lee KW; Suh KS; Bae YS; Kim YJ
Br J Cancer; 2015 Dec; 113(12):1666-76. PubMed ID: 26657650
[TBL] [Abstract][Full Text] [Related]
16. A phase II study of adoptive immunotherapy using dendritic cells pulsed with tumor lysate in patients with hepatocellular carcinoma.
Palmer DH; Midgley RS; Mirza N; Torr EE; Ahmed F; Steele JC; Steven NM; Kerr DJ; Young LS; Adams DH
Hepatology; 2009 Jan; 49(1):124-32. PubMed ID: 18980227
[TBL] [Abstract][Full Text] [Related]
17. Potential therapeutic value of dendritic cells loaded with NY‑ESO‑1 protein for the immunotherapy of advanced hepatocellular carcinoma.
Chen Y; Huang A; Gao M; Yan Y; Zhang W
Int J Mol Med; 2013 Dec; 32(6):1366-72. PubMed ID: 24085111
[TBL] [Abstract][Full Text] [Related]
18. Immunotherapy of hepatocellular carcinoma: is there a place for regulatory T-lymphocyte depletion?
Cany J; Tran L; Gauttier V; Judor JP; Vassaux G; Ferry N; Conchon S
Immunotherapy; 2011 Apr; 3(4 Suppl):32-4. PubMed ID: 21524167
[TBL] [Abstract][Full Text] [Related]
19. Combined therapy of transcatheter hepatic arterial embolization with intratumoral dendritic cell infusion for hepatocellular carcinoma: clinical safety.
Nakamoto Y; Mizukoshi E; Tsuji H; Sakai Y; Kitahara M; Arai K; Yamashita T; Yokoyama K; Mukaida N; Matsushima K; Matsui O; Kaneko S
Clin Exp Immunol; 2007 Feb; 147(2):296-305. PubMed ID: 17223971
[TBL] [Abstract][Full Text] [Related]
20. Phase I/II study of immunotherapy using tumor antigen-pulsed dendritic cells in patients with hepatocellular carcinoma.
Tada F; Abe M; Hirooka M; Ikeda Y; Hiasa Y; Lee Y; Jung NC; Lee WB; Lee HS; Bae YS; Onji M
Int J Oncol; 2012 Nov; 41(5):1601-9. PubMed ID: 22971679
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
